Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_3863_Библиотеки_им_академика_М_И_Перельмана.pdf
Скачиваний:
0
Добавлен:
15.09.2026
Размер:
11 Мб
Скачать
☆
70
P. A. Guido and C. A. Zamora
adrenal adenomas are rich in lipids leading to low attenuation on noncontrast CT.An attenuation value of less than 10 Hounseld units on noncontrast CT has demon­strated a sensitivity of 71% and specicity of 98% for diagnosis of an adenoma [68]. Those that are lipid poor (and which therefore do not have low attenuation on non­contrast CT) can be investigated with contrast-enhanced CT using venous (60–75s) and delayed (15min) scans, although protocols vary by institution [69]. Because of their rich vascularity, adrenal adenomas demonstrate rapid washin and rapid wash­out of contrast material, compared with non-adenomatous lesions which tend to wash out more slowly [67]. The diagnosis of adrenal adenomas on MRI is based on the “chemical shift” phenomenon. Because of slight differences in the magnetic resonant frequencies of water and fat molecules, lipid-rich adenomas demonstrate decreased signal intensity on out-of-phase MRI sequences [69]. Notably, the major­ity of adrenal adenomas are nonfunctioning. The distinction between functioning and nonfunctioning lesions cannot be made on imaging ndings alone and may necessitate adrenal venous sampling [70]. In patients with primary pigmented nodu­lar adrenal disease, the adrenal glands typically show multiple small nodules with interposed atrophy of the adrenal cortex, although ndings can also be normal on CT.In macronodular adrenal hyperplasia, the glands appear massively enlarged and distorted with multiple nodules of varying sizes (Fig.4.7) [71].
Adrenal cortical carcinomas are aggressive malignancies that may result in ACTH-independent hypercortisolism or primary aldosteronism. The majority are large at presentation and commonly present with necrosis, hemorrhage, and hetero­geneous contrast enhancement [72]. Calcication is seen in 24% of patients [73]. Signal intensities on MRI are variable and depend on the extent of hemorrhage, necrosis, and calcication [74].
Fig. 4.7 Axial post­contrast CT demonstrates marked enlargement of the adrenal glands with nodules of varying sizes (arrows) in a patient with hypercortisolism secondary to ACTH-independent macronodular adrenal hyperplasia. (Image courtesy of Israel Saramago, MD, UNC Health, Chapel Hill, NC)
4 Clinical, Laboratory, andRadiological Diagnosis ofHypercortisolism
71

References

1. Lindholm J, Juul S, Jørgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, Hagen C,
Jørgensen J, Kosteljanetz M, Kristensen L, Laurberg P, Schmidt K, Weeke J.Incidence and late prognosis of Cushing’s syndrome: a population-based study. J Clin Endocrinol Metab. 2001;86(1):117–23.
2. Bolland MJ, Holdaway IM, Berkeley JE, Lim S, Dranseld WJ, Conaglen JV, Croxson MS,
Gamble GD, Hunt PJ, Toomath RJ.Mortality and morbidity in Cushing’s syndrome in New Zealand. Clin Endocrinol. 2011;75(4):436–42.
3. Steffensen C, Bak AM, Rubeck KZ, Jørgensen JO. Epidemiology of Cushing’s syndrome.
Neuroendocrinology. 2010;92(Suppl 1):1–5.
4. Valassi E, Santos A, Yaneva M, Tóth M, Strasburger CJ, Chanson P, Wass JA, Chabre O, Pfeifer
M, Feelders RA, Tsagarakis S, Trainer PJ, Franz H, Zopf K, Zacharieva S, Lamberts SW, Tabarin A, Webb SM, ERCUSYN Study Group. The European Registry on Cushing’s syn­drome: 2-year experience. Baseline demographic and clinical characteristics. Eur J Endocrinol. 2011;165(3):383–92.
5. Portereld JR, Thompson GB, Young WF Jr, Chow JT, Fryrear RS, van Heerden JA, Farley
DR, Atkinson JL, Meyer FB, Abboud CF, Nippoldt TB, Natt N, Erickson D, Vella A, Carpenter PC, Richards M, Carney JA, Larson D, Schleck C, Churchward M, Grant CS. Surgery for Cushing’s syndrome: an historical review and recent ten-year experience. World J Surg. 2008;32(5):659–77.
6. Graversen D, Vestergaard P, Stochholm K, Gravholt CH, Jørgensen JO.Mortality in Cushing’s
syndrome: a systematic review and meta-analysis. Eur J Intern Med. 2012;23(3):278–82.
7. Yaneva M, Kalinov K, Zacharieva S.Mortality in Cushing’s syndrome: data from 386 patients
from a single tertiary referral center. Eur J Endocrinol. 2013;169(5):621–7.
8. Catargi B, Rigalleau V, Poussin A, Ronci-Chaix N, Bex V, Vergnot V, Gin H, Roger P,
Tabarin A. Occult Cushing’s syndrome in type-2 diabetes. J Clin Endocrinol Metab. 2003;88(12):5808–13.
9. Chiodini I, Mascia ML, Muscarella S, Battista C, Minisola S, Arosio M, Santini SA, Guglielmi
G, Carnevale V, Scillitani A. Subclinical hypercortisolism among outpatients referred for osteoporosis. Ann Intern Med. 2007;147(8):541–8.
10. Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori
VM.The diagnosis of Cushing’s syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(5):1526–40.
11. Katznelson L, Bogan JS, Trob JR, Schoenfeld DA, Hedley-Whyte ET, Hsu DW, Zervas NT,
Swearingen B, Sleeper M, Klibanski A. Biochemical assessment of Cushing’s disease in patients with corticotroph macroadenomas. J Clin Endocrinol Metab. 1998;83(5):1619–23.
12. Zhou Y, Zhang X, Klibanski A.Genetic and epigenetic mutations of tumor suppressive genes
in sporadic pituitary adenoma. Mol Cell Endocrinol. 2014;386(1–2):16–33.
13. Huizenga NA, de Lange P, Koper JW, Clayton RN, Farrell WE, van der Lely AJ, Brinkmann
AO, de Jong FH, Lamberts SW. Human adrenocorticotropin-secreting pituitary adeno­mas show frequent loss of heterozygosity at the glucocorticoid receptor gene locus. J Clin Endocrinol Metab. 1998;83(3):917–21.
14. Raff H, Findling JW. A physiologic approach to diagnosis of the Cushing syndrome. Ann
Intern Med. 2003;138(12):980–91.
15. Aniszewski JP, Young WF Jr, Thompson GB, Grant CS, van Heerden JA.Cushing syndrome
due to ectopic adrenocorticotropic hormone secretion. World J Surg. 2001;25(7):934–40.
16. de Keyzer Y, Lenne F, Auzan C, Jégou S, René P, Vaudry H, Kuhn JM, Luton JP, Clauser E,
Bertagna X.The pituitary V3 vasopressin receptor and the corticotroph phenotype in ectopic ACTH syndrome. J Clin Invest. 1996;97(5):1311–8.
17. Zilbermint M, Stratakis CA.Protein kinase A defects and cortisol-producing adrenal tumors.
Curr Opin Endocrinol Diabetes Obes. 2015;22(3):157–62.
72
18. Bourdeau I, Lampron A, Costa MH, Tadjine M, Lacroix A. Adrenocorticotropic hormone-
independent Cushing’s syndrome. Curr Opin Endocrinol Diabetes Obes. 2007;14(3):219–25.
19. Allolio B, Fassnacht M.Clinical review: adrenocortical carcinoma: clinical update. J Clin
Endocrinol Metab. 2006;91(6):2027–37.
20. Luton JP, Cerdas S, Billaud L, Thomas G, Guilhaume B, Bertagna X, Laudat MH, Louvel A,
Chapuis Y, Blondeau P, etal. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med. 1990;322(17):1195–201.
21. Koch CA, Pacak K, Chrousos GP. The molecular pathogenesis of hereditary and sporadic
adrenocortical and adrenomedullary tumors. J Clin Endocrinol Metab. 2002;87(12):5367–84.
22. Hsiao HP, Kirschner LS, Bourdeau I, Keil MF, Boikos SA, Verma S, Robinson-White AJ,
Nesterova M, Lacroix A, Stratakis CA.Clinical and genetic heterogeneity, overlap with other tumor syndromes, and atypical glucocorticoid hormone secretion in adrenocorticotropin­independent macronodular adrenal hyperplasia compared with other adrenocortical tumors. J Clin Endocrinol Metab. 2009;94(8):2930–7.
23. De Venanzi A, Alencar GA, Bourdeau I, Fragoso MC, Lacroix A.Primary bilateral macronod-
ular adrenal hyperplasia. Curr Opin Endocrinol Diabetes Obes. 2014;21(3):177–84.
24. Stratakis CA, Kirschner LS, Carney JA.Clinical and molecular features of the Carney com-
plex: diagnostic criteria and recommendations for patient evaluation. J Clin Endocrinol Metab. 2001;86(9):4041–6.
25. Wajchenberg BL, Bosco A, Marone MM, Levin S, Rocha M, Lerário AC, Nery M, Goldman J,
Liberman B.Estimation of body fat and lean tissue distribution by dual energy X-ray absorp­tiometry and abdominal body fat evaluation by computed tomography in Cushing’s disease. J Clin Endocrinol Metab. 1995;80(9):2791–4.
26. Corenblum B, Kwan T, Gee S, Wong NC.Bedside assessment of skin-fold thickness. A useful
measurement for distinguishing Cushing’s disease from other causes of hirsutism and oligo­menorrhea. Arch Intern Med. 1994;154(7):777–81.
27. Pivonello R, Isidori AM, De Martino MC, Newell-Price J, Biller BM, Colao A.Complications
of Cushing’s syndrome: state of the art. Lancet Diabetes Endocrinol. 2016;4(7):611–29.
28. Dekkers OM, Horváth-Puhó E, Jørgensen JO, Cannegieter SC, Ehrenstein V, Vandenbroucke
JP, Pereira AM, Sørensen HT.Multisystem morbidity and mortality in Cushing’s syndrome: a cohort study. J Clin Endocrinol Metab. 2013;98(6):2277–84.
29. Mancini T, Kola B, Mantero F, Boscaro M, Arnaldi G.High cardiovascular risk in patients
with Cushing’s syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol. 2004;61(6):768–77.
30. Van Zaane B, Nur E, Squizzato A, Dekkers OM, Twickler MT, Fliers E, Gerdes VE, Büller
HR, Brandjes DP.Hypercoagulable state in Cushing’s syndrome: a systematic review. J Clin Endocrinol Metab. 2009;94(8):2743–50.
31. Ntali G, Asimakopoulou A, Siamatras T, Komninos J, Vassiliadi D, Tzanela M, Tsagarakis S,
Grossman AB, Wass JA, Karavitaki N.Mortality in Cushing’s syndrome: systematic analysis of a large series with prolonged follow-up. Eur J Endocrinol. 2013;169(5):715–23.
32. Sarlis NJ, Chanock SJ, Nieman LK.Cortisolemic indices predict severe infections in Cushing
syndrome due to ectopic production of adrenocorticotropin. J Clin Endocrinol Metab. 2000;85(1):42–7.
33. Pivonello R, Simeoli C, De Martino MC, Cozzolino A, De Leo M, Iacuaniello D, Pivonello
C, Negri M, Pellecchia MT, Iasevoli F, Colao A.Neuropsychiatric disorders in Cushing’s syn­drome. Front Neurosci. 2015;9:129.
34. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ,
Montori VM.Accuracy of diagnostic tests for Cushing’s syndrome: a systematic review and metaanalyses. J Clin Endocrinol Metab. 2008;93(5):1553–62.
35. Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, Fava GA, Findling
JW, Gaillard RC, Grossman AB, Kola B, Lacroix A, Mancini T, Mantero F, Newell-Price J, Nieman LK, Sonino N, Vance ML, Giustina A, Boscaro M.Diagnosis and complications of Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab. 2003;88(12):5593–602.
P. A. Guido and C. A. Zamora
4 Clinical, Laboratory, andRadiological Diagnosis ofHypercortisolism
36. Lacroix A, Feelders RA, Stratakis CA, Nieman LK. Cushing’s syndrome. Lancet.
2015;386(9996):913–27.
37. Reimondo G, Paccotti P, Minetto M, Termine A, Stura G, Bergui M, Angeli A, Terzolo
M.The corticotrophin-releasing hormone test is the most reliable noninvasive method to dif­ferentiate pituitary from ectopic ACTH secretion in Cushing’s syndrome. Clin Endocrinol. 2003;58(6):718–24.
38. Dichek HL, Nieman LK, Oldeld EH, Pass HI, Malley JD, Cutler GB Jr. A comparison of the
standard high dose dexamethasone suppression test and the overnight 8-mg dexamethasone suppression test for the differential diagnosis of adrenocorticotropin-dependent Cushing’s syn­drome. J Clin Endocrinol Metab. 1994;78(2):418–22.
39. Peck WW, Dillon WP, Norman D, Newton TH, Wilson CB.High-resolution MR imaging of
pituitary microadenomas at 1.5 T: experience with Cushing disease. AJR Am J Roentgenol. 1989;152(1):145–51.
40. Sakamoto Y, Takahashi M, Korogi Y, Bussaka H, Ushio Y. Normal and abnormal pituitary
glands: gadopentetate dimeglumine-enhanced MR imaging. Radiology. 1991;178(2):441–5.
41. Friedman TC, Zuckerbraun E, Lee ML, Kabil MS, Shahinian H.Dynamic pituitary MRI has
high sensitivity and specicity for the diagnosis of mild Cushing’s syndrome and should be part of the initial workup. Horm Metab Res. 2007;39(6):451–6.
42. Tabarin A, Laurent F, Catargi B, Olivier-Puel F, Lescene R, Berge J, etal. Comparative evalu-
ation of conventional and dynamic magnetic resonance imaging of the pituitary gland for the diagnosis of Cushing’s disease. Clin Endocrinol. 1998;49(3):293–300.
43. Grober Y, Grober H, Wintermark M, Jane JA, Oldeld EH.Comparison of MRI techniques for
detecting microadenomas in Cushing’s disease. J Neurosurg. 2018;128(4):1051–7.
44. Lang M, Habboub G, Moon D, Bandyopadhyay A, Silva D, Kennedy L, etal. Comparison of
constructive interference in steady-state and T1-weighted MRI sequence at detecting pituitary adenomas in Cushing’s disease patients. J Neurol Surg B Skull Base. 2018;79(6):593–8.
45. Ajlan A, Achrol AS, Albakr A, Feroze AH, Westbroek EM, Hwang P, etal. Cavernous sinus
involvement by pituitary adenomas: clinical implications and outcomes of endoscopic endo­nasal resection. J Neurol Surg B Skull Base. 2017;78(3):273–82.
46. Knosp E, Steiner E, Kitz K, Matula C. Pituitary adenomas with invasion of the cavernous
sinus space: a magnetic resonance imaging classication compared with surgical ndings. Neurosurgery. 1993;33(4):610–7; discussion 7–8
47. Micko AS, Wohrer A, Wolfsberger S, Knosp E.Invasion of the cavernous sinus space in pitu-
itary adenomas: endoscopic verication and its correlation with an MRI-based classication. J Neurosurg. 2015;122(4):803–11.
48. Buchy M, Lapras V, Rabilloud M, Vasiljevic A, Borson-Chazot F, Jouanneau E, etal. Predicting
early post-operative remission in pituitary adenomas: evaluation of the modied knosp clas­sication. Pituitary. 2019;22(5):467–75.
49. Cottier JP, Destrieux C, Brunereau L, Bertrand P, Moreau L, Jan M, et al. Cavernous sinus
invasion by pituitary adenoma: MR imaging. Radiology. 2000;215(2):463–9.
50. Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing’s syndrome. Lancet.
2006;367(9522):1605–17.
51. Wagner-Bartak NA, Baiomy A, Habra MA, Mukhi SV, Morani AC, Korivi BR, etal. Cushing
syndrome: diagnostic workup and imaging features, with clinical and pathologic correlation. AJR Am J Roentgenol. 2017;209(1):19–32.
52. Ejaz S, Vassilopoulou-Sellin R, Busaidy NL, Hu MI, Waguespack SG, Jimenez C, et al.
Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion: the University of Texas MD Anderson Cancer Center Experience. Cancer. 2011;117(19):4381–9.
53. Zwiebel BR, Austin JH, Grimes MM.Bronchial carcinoid tumors: assessment with CT of
location and intratumoral calcication in 31 patients. Radiology. 1991;179(2):483–6.
54. Jeung MY, Gasser B, Gangi A, Charneau D, Ducroq X, Kessler R, etal. Bronchial carcinoid
tumors of the thorax: spectrum of radiologic ndings. Radiographics. 2002;22(2):351–65.
73
74
55. Jiang Y, Hou G, Cheng W.The utility of 18F-FDG and 68Ga-DOTA-peptide PET/CT in the
evaluation of primary pulmonary carcinoid: a systematic review and meta-analysis. Medicine (Baltimore). 2019;98(10):e14769.
56. Tatci E, Ozmen O, Gokcek A, Biner IU, Ozaydin E, Kaya S, etal. 18F-FDG PET/CT rarely
provides additional information other than primary tumor detection in patients with pulmonary carcinoid tumors. Ann Thorac Med. 2014;9(4):227–31.
57. Deppen SA, Liu E, Blume JD, Clanton J, Shi C, Jones-Jackson LB, etal. Safety and efcacy
of 68Ga-DOTATATE PET/CT for diagnosis, staging, and treatment management of neuroen­docrine tumors. J Nucl Med. 2016;57(5):708–14.
58. Carter BW, Glisson BS, Truong MT, Erasmus JJ.Small cell lung carcinoma: staging, imaging,
and treatment considerations. Radiographics. 2014;34(6):1707–21.
59. Lee D, Rho JY, Kang S, Yoo KJ, Choi HJ.CT ndings of small cell lung carcinoma: can rec-
ognizable features be found? Medicine (Baltimore). 2016;95(47):e5426.
60. Kut V, Spies W, Spies S, Gooding W, Argiris A.Staging and monitoring of small cell lung
cancer using [18F]uoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET). Am J Clin Oncol. 2007;30(1):45–50.
61. Lewis RB, Lattin GE Jr, Paal E.Pancreatic endocrine tumors: radiologic-clinicopathologic
correlation. Radiographics. 2010;30(6):1445–64.
62. Tamm EP, Bhosale P, Lee JH, Rohren EM.State-of-the-art imaging of pancreatic neuroendo-
crine tumors. Surg Oncol Clin N Am. 2016;25(2):375–400.
63. Levy AD, Sobin LH.From the archives of the AFIP: gastrointestinal carcinoids: imaging fea-
tures with clinicopathologic comparison. Radiographics. 2007;27(1):237–57.
64. Ganeshan D, Bhosale P, Yang T, Kundra V.Imaging features of carcinoid tumors of the gastro-
intestinal tract. AJR Am J Roentgenol. 2013;201(4):773–86.
65. Giambelluca D, Cannella R, Midiri M, Salvaggio G.The “spoke wheel” sign in mesenteric
carcinoid. Abdom Radiol (NY). 2019;44(5):1949–50.
66. Evangelista L, Ravelli I, Bignotto A, Cecchin D, Zucchetta P.Ga-68 DOTA-peptides and F-18
FDG PET/CT in patients with neuroendocrine tumor: a review. Clin Imaging. 2020;67:113–6.
67. Lattin GE Jr, Sturgill ED, Tujo CA, Marko J, Sanchez-Maldonado KW, Craig WD, etal. From
the radiologic pathology archives: adrenal tumors and tumor-like conditions in the adult: radiologic-pathologic correlation. Radiographics. 2014;34(3):805–29.
68. Boland GW, Lee MJ, Gazelle GS, Halpern EF, McNicholas MM, Mueller PR.Characterization
of adrenal masses using unenhanced CT: an analysis of the CT literature. AJR Am J Roentgenol. 1998;171(1):201–4.
69. Blake MA, Cronin CG, Boland GW. Adrenal imaging. AJR Am J Roentgenol.
2010;194(6):1450–60.
70. Papakokkinou E, Jakobsson H, Sakinis A, Muth A, Wangberg B, Ehn O, etal. Adrenal venous
sampling in patients with ACTH-independent hypercortisolism. Endocrine. 2019;66(2):338–48.
71. Rockall AG, Babar SA, Sohaib SA, Isidori AM, Diaz-Cano S, Monson JP, etal. CT and MR
imaging of the adrenal glands in ACTH-independent Cushing syndrome. Radiographics. 2004;24(2):435–52.
72. Bharwani N, Rockall AG, Sahdev A, Gueorguiev M, Drake W, Grossman AB, et al.
Adrenocortical carcinoma: the range of appearances on CT and MRI.AJR Am J Roentgenol. 2011;196(6):W706–14.
73. Fishman EK, Deutch BM, Hartman DS, Goldman SM, Zerhouni EA, Siegelman SS.Primary
adrenocortical carcinoma: CT evaluation with clinical correlation. AJR Am J Roentgenol. 1987;148(3):531–5.
74. Elsayes KM, Mukundan G, Narra VR, Lewis JS Jr, Shirkhoda A, Farooki A, etal. Adrenal
masses: MR imaging features with pathologic correlation. Radiographics. 2004;24(Suppl
1):S73–86.
P. A. Guido and C. A. Zamora
Chapter 5
Clinical, Laboratory, andRadiological Diagnosis ofPancreatic Islet Cell Tumors
JashalynnGerman, LaurenM.B.Burke, andJenniferV.Rowell

Introduction

Neuroendocrine tumors (NETs) include a diverse group of tumors that stem from a lineage of sensory/neural and secretory cells. There is heterogeneity among specic tumor types, but they share certain biological characteristics. NETs are predominately located within the bronchopulmonary and gastrointestinal systems [1]. For the scope of this chapter, we will focus on a subset of NETs that derive from the pancreas. Pancreatic endocrine tumors (PETs) may also be referred to as pancreatic neuroendocrine tumors, as pancreatic islet cell tumors, and, historically, as islet of Langerhans tumors [2].
The diagnosis of PETs is based on clinical presentation, laboratory data, and, often, a variety of imaging ndings, all of which may vary based on the specic neoplasm. PETs may range in presentation from nonfunctioning to hormone­secreting tumors or aggressive debilitating malignancies [2]. Nonfunctioning tumors may be discovered incidentally on imaging, and patients may be without noticeable symptoms, while other patients may present with nonspecic symptoms such as abdominal pain, which may be due to local compression/mass effect sec­ondary to primary tumor growth, vascular invasion, or metastatic disease [3]. Functional PETs may present with a specic pattern of syndromes due to ectopic release of hormones, including insulinomas, gastrinomas, VIPomas, etc. [4–7]. This chapter will discuss these functional PETs in more detail (Table5.1).
J. German (*) · J. V. Rowell Department of Medicine, Division of Endocrinology, Metabolism and Nutrition, Duke University, Durham, NC, USA e-mail: Jashalynn.german@duke.edu; Jennifer.rowell@duke.edu
L. M. B. Burke Department of Radiology, Division of Abdominal Imaging, University of North Carolina School of Medicine, Chapel Hill, NC, USA e-mail: Lauren_burke@med.unc.edu
Switzerland AG 2022 H. Yu et al. (eds.), Diagnosis and Management of Endocrine Disorders in Interventional Radiology, https://doi.org/10.1007/978-3-030-87189-5_5
75© The Author(s), under exclusive license to Springer Nature
76
Table 5.1 Tumor characteristics
Tumor name (associated hormone)
Gastrinoma (gastrin)
Glucagonoma (glucagon)
Insulinoma (insulin)
Somatostatinoma (somatostatin)
Estimated incidence
1–3 per million population
Less than
0.1 per million population
1–2 per million population
Less than
0.1 per million population
Clinical presentation characteristics Laboratory data
Recurrent peptic ulcer disease, severe gastroesophageal reux, diarrhea
Necrolytic migratory erythema, new-onset diabetes mellitus or worsening glycemia, higher risk for acute deep venous thrombosis and pulmonary embolism
Whipple’s triad:
• Conrmatory fasting hypoglycemia
• Neuroglycopenic symptoms and/or autonomic nervous system dysfunction
• Improvement in symptoms with resolution of hypoglycemia
Abdominal pain, triad of glucose intolerance/ diabetes mellitus, cholelithiasis, and steatorrhea
Fasting gastrin levels >500pg/ mL or>vefold the upper limit OR gastrin level rising above 200pg/mL or doubling from baseline after secretin administration
Plasma glucagon levels >500pg/ mL or 10–20-fold from normal reference ranges
All of the following:
• Plasma glucose less than 55mg/ dl
• Insulin ≥3.0 μU/m
• C-peptide
≥0.6ng/mL
• Proinsulin
≥5.0pmol/L
• Negative insulin antibodies
• Negative oral hypoglycemic agent screen
Elevated fasting plasma levels of somatostatin (usually exceeding 30pg/mL)
J. German et al.
Tumor characteristics
MEN1 frequently associated with multiple tumors, high risk of malignancy (approx. half are metastasized at time of diagnosis)
Typically a solitary tumor with a relatively larger size than other panNets, and approximately 50–80% are metastatic at diagnosis
Solitary neoplasms or multiple pancreatic tumors which may be benign or malignant in nature
Larger primary tumors (median size pancreatic tumor 4.25cm) and>70% are malignant with the majority having metastasis at time of diagnosis
5 Clinical, Laboratory, andRadiological Diagnosis ofPancreatic Islet Cell Tumors
Table 5.1 (continued)
Tumor name (associated hormone)
VIPoma (vasoactive intestinal peptide)
Estimated incidence
0.1 per million population
Clinical presentation characteristics Laboratory data
Recurrent episodes of facial ushing, severe secretory watery diarrhea, hypokalemia, and hypochlorhydria or achlorhydria
VIP levels higher than 500pg/mL
Tumor characteristics
More than 60% of VIPomas are malignant, with up to 60% having metastasized to lymph nodes, liver, kidneys, or bone
77
Etiology/Physiology
Historically, gastroenteropancreatic NETs were classied based on embryologic origin, with tumors of the pancreas considered to arise from the foregut along with tumors of the pulmonary tree, stomach, gallbladder, and duodenum [8]. The pan­creas has exocrine and endocrine functions. The majority of the gland is made up of acinar cells, involved in exocrine function pathways, and, to a lesser extent, areas of secretory tissue formally called islet of Langerhans cells. These specialized secre­tory cells arise from endoderm and neuroectodermal precursors [9]. PETs originate from these heterogeneous populations of cells, with shared characteristics including amine and neuropeptide hormone production and secretion in dense-core vesi­cles [10].
Gastroenteropancreatic endocrine cells have characteristic neuroendocrine markers, including synaptophysin, the most sensitive, and chromogranin A, the most specic marker [11]. In addition, there are additional markers such as CDX2, Islet 1 (ISL-1), which are specic to endocrine cell subtypes and are ben­ecial in instances of metastatic disease from an unknown primary site [12]. PETs may present sporadically or in association with hereditary genetic muta­tions that predispose patients to well-differentiated NETs such as multiple endo­crine neoplasia syndrome 1 (MEN1), neurobromatosis 1, and von Hippel-Lindau disease [1].
The World Health Organization (WHO) has released guidance on the classi­cation of NETs based on histologic features. The grading of NETs is based on mitotic counts and the Ki-67 labeling index. The American Joint Committee on Cancer (AJCC) staging of gastroenteropancreatic NETs uses a TNM system based on primary tumor characteristics. The TNM system involves assessing the primary tumor size (<2cm, 2–4 cm, >4 cm), presence of invasion of adjacent organs, involvement of regional lymph nodes, and distant metastasis (hepatic vs. extrahepatic) [13].
78
J. German et al.
Epidemiology
The incidence of all NET is estimated to have increased from 3.6- to 4.8-fold over the past four decades [14–16]. The incidence of gastroenteropancreatic NET has increased over recent years, now annually, approximating 5.25 per 100,000 [17]. The current incidence of PETs is estimated to be 0.32–0.8 per 100,000 cases [18]. Rising incidence is related to advances in imaging technology and an aging popula­tion [19, 20].
According to the Surveillance, Epidemiology, and End Results (SEER) database, from 1973 to 2000, most PETs diagnosed were nonfunctional tumors (90.8%). Nonfunctional PETs include tumors that do not produce hormones, tumors that pro­duce hormones at a low enough level to not cause classic syndromes, or tumors that produce hormones but do not cause symptoms. Examples include pancreatic poly­peptide, chromogranin A, ghrelin, calcitonin, or neurotensin. Chromogranin A is detectable in the plasma of patients with a range of neuroendocrine neoplasms, including nonfunctional PETs. Patients who present with PETs in the setting of genetic mutations such as MEN1 are more likely to present at younger ages and are more likely to have multifocal tumors. Sporadic cases commonly present with soli­tary masses during the 5th decade of life [21].

Insulinoma

Etiology/Pathophysiology
Insulinomas are PETs that secrete excessive amounts of insulin, a peptide hormone that has effects on glucose metabolism, including inhibition of glycogenolysis and gluconeogenesis, increased glucose transport into fat and muscle, increased gly­colysis in fat and muscle, and stimulation of glycogen synthesis [22]. Evolving research has brought new histological data on the origin of insulinomas. It is believed that these tumors arise from cells of the ductular/acinar system of the pan­creas rather than from neoplastic proliferation of islet cells, as previously thought [23]. Presenting symptoms are related to severe hypoglycemia due to loss of homeo­stasis of the pathways mentioned above.
Epidemiology
Insulinomas are one of the most common types of functional PETs, with an annual incidence of 1–2 per million [18]. Insulinomas can present as solitary neoplasms or multiple pancreatic tumors, which may be benign or malignant in nature,
5 Clinical, Laboratory, andRadiological Diagnosis ofPancreatic Islet Cell Tumors
dened as the presence of metastases. The majority of insulinomas are sporadic and are usually diagnosed after the 5th decade of life, while the minority of insu­linomas related to MEN1 syndrome (10%) tend to occur before the 4th decade of life [24, 25].
79
Clinical Evaluation
Patients with insulinomas often present with Whipple’s triad, consisting of (1) labo­ratory proven hypoglycemia, (2) neuroglycopenic symptoms (e.g., vision changes, confusion, coma, or seizure) and autonomic dysfunction (e.g., diaphoresis, palpita­tions, tremors, anxiety), and (3) improvement in symptoms with resolution of hypo­glycemia [1, 24]. Hypoglycemia due to insulinomas is often related to exercise or periods of fasting [24]; a subset of patients experience postprandial hypoglyce­mia [25].
Laboratory Evaluation
Before pursuing imaging or invasive procedures, it is important to exclude other more common causes of hypoglycemia, including factitious hypoglycemia or that which is secondary to other medical conditions such as severe liver or renal impair­ment or sepsis. Insulinomas can be diagnosed based on biochemical evaluation dur­ing medically supervised fasting periods, which traditionally can last up to 72h. A positive fasting test that is consistent with excess endogenous insulin includes a conrmatory negative oral hypoglycemic agent screen, plasma concentrations of glucose less than 55mg/dl (3.0mmol/L), insulin of at least 3.0 μU/mL (18pmol/L), C-peptide of at least 0.6ng/mL (0.2nmol/L), and proinsulin of at least 5.0pmol/L [26, 27].

Gastrinoma

Etiology/Pathophysiology
Gastrinomas are PETs that secrete excessive amounts of gastrin. This peptide hor­mone stimulates gastric parietal cells directly and indirectly by way of histamine­secreting enterochromafn-like (ECL) cells with the ultimate response of overproduction of gastric acid. High volumes of gastric acid overwhelm the pan­creas’s ability to neutralize intestinal contents. Drastically increased acidity of